SHINE Technologies has partnered with Antelope Surgical Solutions, a biotech company pioneering next-generation multimodal radiopharmaceuticals, the company announced recently.

According to a release, the supply agreement will accelerate Antelope’s clinical development of its targeted radiopharmaceutical candidates.

Under the agreement, SHINE will provide GMP-grade n.c.a. lutetium-177 (Lu-177), a therapeutic isotope that enhances Antelope’s pipeline of small-molecule drugs.

The financial terms of the agreement were not disclosed.

Antelope Surgical Solutions is headquartered in New York.